Back to top

gene-editing: Archive

Zacks Equity Research

Iovance's (IOVA) Q3 Earnings Beat Estimates, Revenues Nil

Iovance Biotherapeutics (IOVA) reports a wider-than-expected loss in Q3. The company is on track to initiate a rolling BLA submission for lifileucel in melanoma later this month.

BMYPositive Net Change MRKPositive Net Change CLLSNegative Net Change IOVANegative Net Change